Latest Annual Filing
For Fiscal Year Ending Dec 31, 2023
Report Links
Latest Financial Results
Q3 2024
Quarter Ended Sep 30, 2024
Company Overview
Artelo Biosciences, Inc. is a clinical stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways including the endocannabinoid system. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, pain, neuropathy, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies.
IR Contacts
Company
Artelo Biosciences, Inc.
505 Lomas Santa Fe Drive
Suite 160
Solana Beach, CA 92075
Investor Relations
Crescendo Communications, LLC
T: 212-671-1020
ARTL@crescendo-ir.com
Transfer Agent
Equiniti Trust Company, LLC (“EQ”)
55 Challenger Road, Floor 2
Ridgefield Park, NJ 07660
T: U.S. Residents: 1-800-401-1957 | Canada or U.S. Virgin Island Residents: 1-800-468-9716
helpAST@equiniti.com
https://www.astfinancial.com/